| Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer H Hariu, Y Hirohashi, T Torigoe, H Asanuma, M Hariu, Y Tamura, K Aketa, ... Clinical cancer research 11 (3), 1000-1009, 2005 | 276 | 2005 |
| An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin Y Hirohashi, T Torigoe, A Maeda, Y Nabeta, K Kamiguchi, T Sato, J Yoda, ... Clinical cancer research 8 (6), 1731-1739, 2002 | 255 | 2002 |
| Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT … H Asanuma, T Torigoe, K Kamiguchi, Y Hirohashi, T Ohmura, K Hirata, ... Cancer research 65 (23), 11018-11025, 2005 | 240 | 2005 |
| Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer T Tsuruma, F Hata, T Torigoe, T Furuhata, S Idenoue, T Kurotaki, ... Journal of translational medicine 2, 1-11, 2004 | 236 | 2004 |
| Preferential expression of cancer/testis genes in cancer stem‐like cells: proposal of a novel sub‐category, cancer/testis/stem gene R Yamada, A Takahashi, T Torigoe, R Morita, Y Tamura, T Tsukahara, ... Tissue antigens 81 (6), 428-434, 2013 | 226 | 2013 |
| Detection of autoantibodies to livin and survivin in Sera from lung cancer patients A Yagihashi, K Asanuma, D Kobayashi, N Tsuji, Y Shijubo, S Abe, ... Lung cancer 48 (2), 217-221, 2005 | 193 | 2005 |
| A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins S Idenoue, Y Hirohashi, T Torigoe, Y Sato, Y Tamura, H Hariu, ... Clinical cancer research 11 (4), 1474-1482, 2005 | 183 | 2005 |
| Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells S Inoda, Y Hirohashi, T Torigoe, R Morita, A Takahashi, H Asanuma, ... The American journal of pathology 178 (4), 1805-1813, 2011 | 160 | 2011 |
| HSP DNAJB8 controls tumor-initiating ability in renal cancer stem–like cells S Nishizawa, Y Hirohashi, T Torigoe, A Takahashi, Y Tamura, T Mori, ... Cancer research 72 (11), 2844-2854, 2012 | 132 | 2012 |
| SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity M Nakatsugawa, A Takahashi, Y Hirohashi, T Torigoe, S Inoda, M Murase, ... Laboratory investigation 91 (12), 1796-1804, 2011 | 130 | 2011 |
| Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway T Kurotaki, Y Tamura, G Ueda, J Oura, G Kutomi, Y Hirohashi, H Sahara, ... The Journal of Immunology 179 (3), 1803-1813, 2007 | 127 | 2007 |
| Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma S Inoda, Y Hirohashi, T Torigoe, M Nakatsugawa, K Kiriyama, ... Journal of Immunotherapy 32 (5), 474-485, 2009 | 126 | 2009 |
| ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis T Kuroda, Y Hirohashi, T Torigoe, K Yasuda, A Takahashi, H Asanuma, ... PloS one 8 (6), e65158, 2013 | 122 | 2013 |
| Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer T Tsuruma, Y Iwayama, T Ohmura, T Katsuramaki, F Hata, T Furuhata, ... Journal of translational medicine 6, 1-11, 2008 | 103 | 2008 |
| High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis Y Michifuri, Y Hirohashi, T Torigoe, A Miyazaki, J Kobayashi, T Sasaki, ... Pathology international 62 (10), 684-689, 2012 | 95 | 2012 |
| Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population K Yasuda, T Torigoe, R Morita, T Kuroda, A Takahashi, J Matsuzaki, ... PloS one 8 (8), e68187, 2013 | 92 | 2013 |
| Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24+ patients with synovial sarcoma Y Sato, Y Nabeta, T Tsukahara, Y Hirohashi, R Syunsui, A Maeda, ... The Journal of Immunology 169 (3), 1611-1618, 2002 | 90 | 2002 |
| Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer A Miyazaki, J Kobayashi, T Torigoe, Y Hirohashi, T Yamamoto, ... Cancer science 102 (2), 324-329, 2011 | 89 | 2011 |
| Immunotherapeutic benefit of α‐interferon (IFNα) in survivin2 B‐derived peptide vaccination for advanced pancreatic cancer patients H Kameshima, T Tsuruma, G Kutomi, H Shima, Y Iwayama, Y Kimura, ... Cancer science 104 (1), 124-129, 2013 | 86 | 2013 |
| Olfactory receptor family 7 subfamily C member 1 is a novel marker of colon cancer–initiating cells and is a potent target of immunotherapy R Morita, Y Hirohashi, T Torigoe, S Ito-Inoda, A Takahashi, T Mariya, ... Clinical Cancer Research 22 (13), 3298-3309, 2016 | 85 | 2016 |
